期刊档案 · 医学-药学
Pharmacological Research
ISSN 1043-6618 · eISSN 1096-1186 · Academic Press Inc. · ENGLAND · Monthly · 创刊 1989
Pharmacological Research 中科院 医学 2区（2025 年升级版，Top 期刊），影响因子 11.72，完全开放获取，APC 约 4,130 美元，近 24 个月 158 篇文章投稿到接收中位 79 天，录用比例较易（社区反馈），2025 年发文 493 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Pharmacological Research 由 Academic Press Inc. 出版，属中科院医学大类（2025 升级版2区，Top 期刊）。按 OpenAlex 近年发文统计，该刊主要发表 Neuroscience and Neuropharmacology Research、Receptor Mechanisms and Signaling、Neuropeptides and Animal Physiology 等主题的论文，这 3 个主题约占 25.8%，主导子领域为 Cellular and Molecular Neuroscience。（根据 OpenAlex 主题统计与中科院分区数据生成）
Bridging across disciplinesAn IUPHAR-affiliated journal, International Union of Basic and Clinical PharmacologyPharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. We provide a venue through which specialists across disciplines can rapidly exchange information in health sciences that pertains to modern pharmacological topics. The journal publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.Invited and unsolicited review articles are welcome.Journal SectionsSpecific sections are dedicated to:The cardiovascular system:CV disease therapy;Signal transduction and receptor pharmacology in the CV system;Target organs;Clinical trials.Neuroscience, including psychopharmacology, and neuroendocrinology:Understanding of the central nervous system in physiological and pathological conditions;Neuropharmacological and molecular mechanisms of learning and memory;Therapeutic and diagnostic challenges for mental illness and neurodegerative diseases;System biology.Oncology:Targeted cancer therapy;Precision medicine and personalized therapy;Signal transduction studies, as related to drug action;Clinical trials.Immunology (clinical and basic):Immune and inflammatory mechanisms including target identification;Immunotherapy and immunotoxicology;Immunopathology;Vaccines and adjuvants;Treatment of infectious diseases.Redox regulators and biological gases in pathophysiology:Oxidative and nitrative stress and cell dysfunction;Redox regulation of signal transduction in various diseases;Pathophysiological roles of NO, CO and H2S;Interaction between oxidants and gaseous mediators in health and disease;Pharmacological modulators of oxidants, free radicals and gaseous transmitters.Renal Pathophysiology and Pharmacology:Acute and chronic kidney injury disease;Metabolic alkalosis and metabolic acidosis in renal disease;Renal excretion in electrolyte disorders;Diabetes insipidus, Diabetic nephropathy;Pathogenesis of glomerular disease;End stage renal disease;Prevention and treatment of nephrotic diseases.Pregnancy Related Pharmacology and Perinatal Therapeutics:Drug effects on the mother and foetus before and after birth;Placental barrier and its relationship with drugs (transportation metabolism and so on);Molecular signalling in placenta and identification of mechanisms beyond drug action in pregnancy;Adverse effects of drugs drug/combination in placenta;Drug repurposing/reprogramming for placenta-related disorders;Regulatory aspects beyond clinical research in pregnant mothers;Placenta remodelling in disease;In vivo models of the diseased placenta;The microbioma;Effects of the environment on pregnancy;Preventive vs therapeutic use of drugs.Pharmacogenomics, Pharmacogenetics and Precision Medicine:We are especially interested in GWAS studies and studies reporting pharmacogenetic data that are relevant in terms of safety and efficacy of drugs. They must provide insight into novel genomic or therapeutic associations that can help guide therapy selection or suggest new indications for established drugs. Studies can also provide details of exceptional responses in limited numbers of patients.We also publish n=1 studies of exceptional responses, provided they are backed up by compelling genomic or experimental data.Studies must include full clinical description of the case, along with details of the response and supporting molecular information. The molecular information should support the clinical observations and offer a definitive pharmacogenomic insight. Standard clinical sequencing assays (Foundation ONE, Genoptix etc) are only appropriate when the therapeutic or phenotypic response is novel. Ideally, the observational patient studies should be supporte
摘自期刊官网 Aims & Scope
研究方向（LetPub）：医学-药学
主编 Emilio Clementi出版商官网
编委会国家分布：中国大陆 50 位（约 29%）；主要国家 中国 50、美国 35、意大利 27、中国澳门 9、法国 6（共 171 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Neuroscience and Neuropharmacology ResearchNeuroscience10.1%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology9.5%
- Neuropeptides and Animal PhysiologyNeuroscience6.3%
- Nitric Oxide and Endothelin EffectsMedicine6.1%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience4.6%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology4.5%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance3.8%
- Human auditory perception and evaluationEngineering3.7%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 1 区 |
Top 期刊：是综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 1 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 1 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 1 区 |
Top 期刊：是综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 1 区 |
Top 期刊：是综述期刊：否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 11.72LetPub ·
- 影响因子（出版商公布）
- 12.2出版商官网 ·
- CiteScore 2026-06
- 19.1LetPub ·
- CiteScore（出版商公布）
- 19.1出版商官网 ·
- SJR 2026-06
- 2.91LetPub ·
- SNIP 2026-06
- 2.16LetPub ·
- h-index
- 118LetPub ·
- h-index
- 223OpenAlex ·
- i10-index
- 6,208OpenAlex ·
- 两年平均被引
- 11.05OpenAlex ·
- 自引率
- 1.6%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 421LetPub ·
逐年发文量 OpenAlex 统计 · 累计 12,338 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 399 | 399 | 360 |
| 2025 | 493 | 493 | 4,425 |
| 2024 | 497 | 497 | 10,557 |
| 2023 | 384 | 384 | 11,428 |
| 2022 | 498 | 219 | 20,991 |
| 2021 | 558 | 149 | 29,320 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
79 天投稿到接收中位数 · P25–P75 63 天 – 102 天
- 接收到上线
- 中位数 2 天（158 篇）
- 投稿到上线
- 中位数 82 天
- 样本
- 158 篇有投稿与接收日期的文章（窗口内共 1,031 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 偏慢,4-8周来源Elsevier官网：平均5.5周LetPub ·
- 平均录用比例（社区反馈）
- 较易LetPub ·
- 投稿到首次决定
- 1 天出版商官网 ·
- 外审后首次决定
- 31 天出版商官网 ·
- 投稿到接收
- 73 天出版商官网 ·
- 接收到发表
- 2 天出版商官网 ·
- 评审方式
- 匿名同行评审LetPub
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取OpenAlex
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 4,130 / EUR 3,860 / GBP 3,310 / JPY 512,240 | — | — | |
| LetPub | USD 4,510 | 有 | — | |
| 出版商官网 | USD 4,510 | — | — |
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
征稿中的专刊6 个，按截稿日期
- Pharmacological Targeting of Tauopathies: Novel Strategies and Therapeutic Challenges截稿
- Stem Cells, Exosomes, and Neurological Diseases: Novel Pharmacological Mechanisms and Translational Therapeutics截稿
- Targeting DNA Repair and Immune Modulation in Cancer Therapy截稿
- Advanced Human Models for Drug Discovery and Immunopharmacology: Organoids, Organ-on-Chip, and Beyond截稿
- Artificial Intelligence and Computational Approaches in Precision and Personalized Phytomedicine towards Improved Drug Efficacy截稿
- AI-Driven Spatial Niches of Cancer Therapeutic Resistance: From Multi-Omics Discovery to Pharmacological Targeting截稿
投稿准备要点3 项，摘自作者指南
- 摘要
- ≤ 250 词
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 不接收
- case reports
接收的文章类型13 种
- case reportOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- letters to the editorOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- meta-analysisOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- opinionOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- opinion articles and perspectivesOpinion articles and Perspectives. These articles provide expert views on future research and clinical trends in specific fields. These articles are solicited b…未说明篇幅
- original articleOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- original articlesOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- perspectiveOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- regular paperOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- research paperOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- review articleOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
- review articles and meta-analysesReview articles and meta-analyses. Review articles and meta-analyses are welcome but should be topical and not just an overview of the literature.未说明篇幅
- short communicationOriginal articles. Original full-length research papers that have not been published previously, except in a preliminary form, may be submitted as regular paper…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
作者在投稿时必须声明在稿件准备过程中使用生成式人工智能工具的情况。 模型中文摘要
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
团体署名指将文章归属于一个明确且具名的作者群体，须在投稿时于标题页声明，并在投稿系统中作为"协作作者组"提交。 模型中文摘要
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
所有作者必须披露可能不当影响或偏袒其工作的与他人或组织的财务和个人关系。 模型中文摘要
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 License options
作者将获得开放获取用户许可选项，建议在选择许可前审查这些选项及资助机构的许可要求。 模型中文摘要
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
该期刊提供开放获取信息页面，供作者了解其开放获取选项。 模型中文摘要
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
该期刊采用单盲同行评审，投稿先由编辑评估，合格稿件通常送至少两名审稿人独立评审，录用与否由编辑决定。 模型中文摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
作者可按Elsevier文章共享政策分享预印本，分享预印本不计为先前发表，该期刊还提供SSRN免费预印本发布服务。 模型中文摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Academic Press Inc.
- 出版国家或地区
- ENGLAND
- 出版语言
- English
- 出版周期
- Monthly
- 创刊年份
- 1989
- ISSN
- 1043-6618
- 电子版 ISSN
- 1096-1186
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
常见问题
关于 Pharmacological Research 的常见问题
Pharmacological Research 是中科院几区期刊？
2025 年升级版分区表中，Pharmacological Research 为医学 2区，小类 药学 1 区，属于 Top 期刊。2026 年新锐版分区表中为医学 1区。不同版本与大小类分区不能混用。
Pharmacological Research 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 11.72，CiteScore 为 19.1，h-index 为 223。
Pharmacological Research 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）158 篇已发表文章登记的日期，投稿到接收的中位数为 79 天（四分位 63–102 天）；投稿社区反馈的平均审稿速度为4–8 周，平均录用比例反馈为“较易”。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Pharmacological Research 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；参考文献格式：顺序编码制（按引用顺序编号）。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Pharmacological Research 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 171 位编委中，中国大陆 50 位（约 29%）；人数最多的国家是 中国（50 位）、美国（35 位）、意大利（27 位）。统计按编委会页面列出的机构国家计，仅供参考。
Pharmacological Research 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Pharmacological Research 被 SCIE、Scopus、DOAJ 收录。
Pharmacological Research 是开放获取期刊吗？版面费多少？
Pharmacological Research 为完全开放获取。APC 约 4,130 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。